The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.
Proceedings of the National Academy of Sciences of the United States of America, Volume 101, Issue 26, 2004, Pages 9861-9866.
Here, we show that the synaptic vesicle protein SV2A is the brain binding site of levetiracetam (LEV), a new antiepileptic drug with a unique activity profile in animal models of seizure and epilepsy. The LEV-binding site is enriched in synaptic vesicles, and photoaffinity labeling of purified synaptic vesicles confirms that it has an app...更多
下载 PDF 全文 (上传PDF)